Irbesartan inhibits advanced glycation end product (AGE)-induced up-regulation of vascular cell adhesion molecule-1 (VCAM-1) mRNA levels in glomerular endothelial cells

Microvascular Research

Volumn 81, Issue 3, 2011, Pages 269-273

  Matsui, Takanori ^a   Nishino, Yuri ^a   Maeda, Sayaka ^a   Takeuchi, Masayoshi ^b   Yamagishi, Sho ichi ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HOKURIKU UNIVERSITY   (Japan)

Author keywords

AGE; Diabetic nephropathy; Oxidative stress; RAS

Indexed keywords

ACETYLCYSTEINE; ADVANCED GLYCATION END PRODUCT; ANGIOTENSIN II; IRBESARTAN; MESSENGER RNA; REACTIVE OXYGEN METABOLITE; VASCULAR CELL ADHESION MOLECULE 1;

ANTIOXIDANT ACTIVITY; ARTICLE; CELL STIMULATION; CONTROLLED STUDY; DIABETIC NEPHROPATHY; ENDOTHELIUM CELL; GENE EXPRESSION REGULATION; GLOMERULUS; HUMAN; HUMAN CELL; INFLAMMATION; INHIBITION KINETICS; MOLECULAR INTERACTION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ACETYLCYSTEINE; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIOXIDANTS; BIPHENYL COMPOUNDS; CELLS, CULTURED; ENDOTHELIAL CELLS; GENE EXPRESSION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; HYDROGEN PEROXIDE; KIDNEY GLOMERULUS; PEPTIDYL-DIPEPTIDASE A; RENIN; SALICYLIC ACIDS; SERUM ALBUMIN, BOVINE; SUPEROXIDES; TETRAZOLES; UP-REGULATION; VASCULAR CELL ADHESION MOLECULE-1;

EID: 79954617011     PISSN: 00262862     EISSN: 10959319     Source Type: Journal    
DOI: 10.1016/j.mvr.2011.01.001     Document Type: Article

References (29)

1. Bolton W.K., Cattran D.C., Williams M.E., Adler S.G., Appel G.B., Cartwright K., Foiles P.G., Freedman B.I., Raskin P., Ratner R.E., Spinowitz B.S., Whittier F.C., Wuerth J.P. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am. J. Nephrol. 2004, 24:32-40. ACTION I Investigator Group.
2. Brownlee M., Cerami A., Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N. Engl. J. Med. 1988, 318:1315-1321.
3. Busch M., Franke S., Rüster C., Wolf G. Advanced glycation end-products and the kidney. Eur. J. Clin. Investig. 2010, 40:742-755.
4. Chow F.Y., Nikolic-Paterson D.J., Ozols E., Atkins R.C., Rollin B.J., Tesch G.H. Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int. 2006, 69:73-80.
5. Cravedi P., Ruggenenti P., Remuzzi G. Intensified inhibition of renin-angiotensin system: a way to improve renal protection?. Curr. Hypertens. Rep. 2005, 9:430-436.
6. Dyer D.G., Blackledge J.A., Thorpe S.R., Baynes J.W. Formation of pentosidine during nonenzymatic browning of proteins by glucose. Identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. J. Biol. Chem. 1991, 266:11654-11660.
7. Fukami K., Ueda S., Yamagishi S., Kato S., Inagaki Y., Takeuchi M., Motomiya Y., Bucala R., Iida S., Tamaki K., Imaizumi T., Cooper M.E., Okuda S. AGEs activate mesangial TGF-beta-Smad signaling via an angiotensin II type I receptor interaction. Kidney Int. 2004, 66:2137-2147.
8. Grandhee S.K., Monnier V.M. Mechanism of formation of the Maillard protein cross-link pentosidine. Glucose, fructose, and ascorbate as pentosidine precursors. J. Biol. Chem. 1991, 266:11649-11653.
9. Kamioka M., Ishibashi T., Sugimoto K., Uekita H., Nagai R., Sakamoto N., Ando K., Ohkawara H., Teramoto T., Maruyama Y., Takeishi Y. Blockade of renin-angiotensin system attenuates advanced glycation end products-mediated signaling pathways. J. Atheroscler. Thromb. 2010, 17:590-600.
10. Lewis E.J., Hunsicker L.G., Clarke W.R., Berl T., Pohl M.A., Lewis J.B., Rits E., Atkins R.C., Raz I. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 2001, 345:851-860. Collaborative Study Group.
11. Liu X.P., Pang Y.J., Zhu W.W., Zhao T.T., Zheng M., Wang Y.B., Sun Z.J., Sun S.J. Benazepril, an angiotensin-converting enzyme inhibitor, alleviates renal injury in spontaneously hypertensive rats by inhibiting advanced glycation end-product-mediated pathways. Clin. Exp. Pharmacol. Physiol. 2009, 36:287-296.
12. Marino M.R., Langenbacher K., Ford N.F., Uderman H.D. Pharmacokinetics and pharmacodynamics of irbesartan in healthy subjects. J. Clin. Pharmacol. 1998, 138:246-255.
13. Min D., Lyon J.G., Bonner J., Twigg S.M., Yue D.K., McLennan S.V. Mesangial cell-derived factors alter monocyte activation and function through inflammatory pathways: possible pathogenic role in diabetic nephropathy. Am. J. Physiol. Ren. Physiol. 2009, 297:F1229-F1237.
14. Navarro J.F., Milena F.J., Mora C., León C., García J. Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: effect of angiotensin-converting enzyme inhibition and pentoxifylline administration. Am. J. Nephrol. 2006, 26:562-570.
15. Ogawa S., Mori T., Nako K., Kato T., Takeuchi K., Ito S. Angiotensin II type 1 receptor blockers reduce urinary oxidative stress markers in hypertensive diabetic nephropathy. Hypertension 2006, 47:699-705.
16. Ruggenenti P., Cravedi P., Remuzzi G. The RAAS in the pathogenesis and treatment of diabetic nephropathy. Nat. Rev. Nephrol. 2010, 6:319-330.
17. Singh R., Alavi N., Singh A.K., Leehey D.J. Role of angiotensin II in glucose-induced inhibition of mesangial matrix degradation. Diabetes 1999, 48:2066-2073.
18. Sourris K.C., Harcourt B.E., Forbes J.M. A new perspective on therapeutic inhibition of advanced glycation in diabetic microvascular complications: common downstream endpoints achieved through disparate therapeutic approaches?. Am. J. Nephrol. 2009, 30:323-335.
19. Takeuchi M., Makita Z., Yanagisawa K., Kameda Y., Koike T. Detection of noncarboxymethyllysine and carboxymethyllysine advanced glycation end products (AGE) in serum of diabetic patients. Mol. Med. 1999, 5:393-405.
20. Vlassara H., Bucala R. Recent progress in advanced glycation and diabetic vascular disease: role of advanced glycation end product receptors. Diabetes 1996, Suppl 3:S65-S66.
21. Vlassara H., Torreggiani M., Post J.B., Zheng F., Uribarri J., Striker G.E. Role of oxidants/inflammation in declining renal function in chronic kidney disease and normal aging. Kidney Int. 2009, Suppl. 114:S3-S11.
22. Wang F., Li M., Cheng L., Zhang T., Hu J., Cao M., Zhao J., Guo R., Gao L., Zhang X. Intervention with cilostazol attenuates renal inflammation in streptozotocin-induced diabetic rats. Life Sci. 2008, 19:828-835.
23. Wendt T., Tanji N., Guo J., Hudson B.I., Bierhaus A., Ramasamy R., Arnold B., Nawroth P.P., Yan S.F., D'Agati V., Schmidt A.M. Glucose, glycation, and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathy. J. Am. Soc. Nephrol. 2003, 14:1383-1395.
24. Yamagishi S., Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr. Pharm. Des. 2005, 11:2279-2299.
25. Yamagishi S., Matsui T. Advanced glycation end products (AGEs), oxidative stress and diabetic nephropathy. Oxid. Med. Cell. Longev. 2010, 3:101-108.
26. Yamagishi S., Nakamura K., Matsui T., Inagaki Y., Takenaka K., Jinnouchi Y., Yoshida Y., Matsuura T., Narama I., Motomiya Y., Takeuchi M., Inoue H., Yoshimura A., Bucala R., Imaizumi T. Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression. J. Biol. Chem. 2006, 281:20213-20220.
27. Yamagishi S., Fukami K., Ueda S., Okuda S. Molecular mechanisms of diabetic nephropathy and its therapeutic intervention. Curr. Drug Targets 2007, 8:952-959.
28. Yamamoto Y., Kato I., Doi T., Yonekura H., Ohashi S., Takeuchi M., Watanabe T., Yamagishi S., Sakurai S., Takasawa S., Okamoto H., Yamamoto H. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J. Clin. Invest. 2001, 108:261-268.
29. Yoshida T., Yamagishi S., Nakamura K., Matsui T., Imaizumi T., Takeuchi M., Koga H., Ueno T., Sata M. Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation. Diabetologia 2006, 49:3094-3099.